The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program® (TAP)


TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.

Since establishment in 2007, TAP has invested >$130 million in over 70 projects.

Four TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA) or included in the National Comprehensive Cancer Network (NCCN) Guidelines:

  • CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML)
  • Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL)
  • Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
  • Duvelisib (Copiktra®), first dual inhibitor of PI3K-delta and gamma pathways included in NCCN Guidelines for patients with all subtypes of peripheral T-cell lymphoma (PTCL) 

Currently, there are over 20 TAP-supported companies with assets in active development, including 4 ongoing registration-enabling clinical studies in blood cancer & 2 beyond blood cancer.

To learn more about TAP:

LLS leverages its over 70-year commitment to cures for blood cancers and has funded over 4000 academic grants and 70 TAP projects since its inception, amounting to $1.3 Billion of support toward disease control and cures. LLS knowledge and know-how in blood cancer drug development is unparalleled, underscored by LLS support for over 85% of the new blood cancer therapies approved in the past 20 years.

To learn more about LLS-supported Research:

Follow LLS